How Has the Induced Pluripotent Stem Cell (iPSC) Market Evolved Historically and What is its Current Size?
The induced pluripotent stem cell (ipsc) market has seen considerable growth due to a variety of factors.
• The market for induced pluripotent stem cell (iPSC) has shown significant expansion in the recent past. The market is projected to leap from $3.3 billion in 2024 to $3.67 billion in 2025, with a compound annual growth rate (CAGR) of 11.3%.
The boost during the historic period is due to the escalation in healthcare spendings, increased funding, growing cognizance of the therapeutic properties of stem cell products, utilization of iPSC for drug discovery, surging demand for individualized medicine, and the cost-effectiveness of iPSC in drug discovery.
What Will Be The Induced Pluripotent Stem Cell (iPSC) Market Size In The Future?
The induced pluripotent stem cell (ipsc) market is expected to maintain its strong growth trajectory in upcoming years.
• The market for induced pluripotent stem cells (iPSC) is predicted to exhibit strong growth in the upcoming years, with projections indicating an expansion to $5.29 billion in 2029 and a compound annual growth rate (CAGR) of 9.6%.
Several factors are contributing to this anticipated growth, such as the rising incidence of chronic and genetic disorders, advancements in genomic projects, creation of IPSC-derived disease models, governmental initiatives, and a swift advancement in technology. The forecast period is also expected to see key trends like the utilization of pluripotent stem cells for tackling Parkinson’s disease, strategic alliances, development of iPSC-derived nk cells, use of iPSC for cell therapy, investment in the research and development of regenerative medicine, creation of IPSC expansion medium, personalization of iPSC, and the application of pluripotent stem cells for type I diabetes.
What Factors Are Driving Growth In The Induced Pluripotent Stem Cell (iPSC) Market?
The escalating incidence of enduring diseases is a significant contributor to the expansion of the induced pluripotent stem cell industry. Induced pluripotent stem cells, drawn from any tissue taken from a child or adult, are genetically altered to mimic embryonic stem cells, making them a potential treatment for chronic ailments like heart disease, cancer, stroke, and diabetes. The Partnership to Fight Chronic Disorder (PFCD) authored a report indicating that 45% of 133 million Americans, suffer from at least one enduring ailment. Additionally, it's approximated that 1.7 million deaths in the USA, approximately 7 out of 10, result from chronic ailments, a number that could potentially be reduced with induced pluripotent stem cell therapy. This surge in chronic diseases is fuelling the need for induced pluripotent stem cell treatment in the market.
What are the Market Segments in the Induced Pluripotent Stem Cell (iPSC) Market?
The induced pluripotent stem cell (iPSC) market covered in this report is segmented –
1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories
Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research
Pre-Book The Induced Pluripotent Stem Cell (iPSC) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Induced Pluripotent Stem Cell (iPSC) Market?
Businesses within the Induced Pluripotent stem cell sector are exploring strategic partnerships and collaborations, which will allow them to break into new geographical markets and enhance their product offerings. For instance, in January 2022, a strategic alliance was formed between Bristol Myers Squibb and Century Therapeutics to produce IPSC-derived allogenic cell therapies designed to treat acute myeloid leukemia and multiple myeloma. Additionally, in May 2022, Evotec and Sernova cooperatively announced their strategic affiliation aimed at creating an IPSC-based beta cell replacement therapy intended to help in treating both Type 1 and Type 2 diabetes.
Who Are the Key Players in the Induced Pluripotent Stem Cell (iPSC) Market?
Major companies operating in the induced pluripotent stem cell (iPSC) market include:
• FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics. Inc)
• Thermo Fisher Scientific. Inc
• Takara Bio. Inc
• Lonza Group AG
• Astellas Pharma Inc
• ViaCyte. Inc
• Ncardia
• REPROCELL USA. Inc
• Japan Tissue Engineering Co. Ltd
• Merck KGaA
• Cynata Therapeutics Limited
• Dainippon Sumitomo Pharma
• Shenzhen Bioscience
• Shanghai Cell Therapy Group
• Car-T Bio
• JW therapeutics
• Fosun Kite Biotechnology
• Shanghai UniCar Therapy
• Takaria Bio
• SEED Biosciences SA
• Cellerix
• CellGenix
• NsGene
• TiGenix
• Renuron Group
• Smart Cells
• Genenta Science
• Biocad Rf
• MSD
• Pfizer
• Roche
• Pharmasyntez
• Selvita
• Mabion
• Pure Biologics
• OncoArendi Therapeutics
• Proteon Pharmaceuticals
• GlaxoSmithKline
• Parexel
• Bayer
• Fate Therapeutics
• Athersys
• BrainStorm Cell Therapeutics
• Cellular Biomedicine Group
• Pluristem Therapeutics
• Gamida Cell
• VistaGen Therapeutics
• Caladrius Biosciences
• BioCanRx
• CellCAN
• CCRM
• C3i
• BioCells Argentina
• Stem Cells
• Royan Stem Cell Technology Co.
• Next BioSciences
• CryoSave
• BioHeart
What are the Regional Insights into the Induced Pluripotent Stem Cell (iPSC) Market?
North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
